戻る
ADC Therapeutics SA (ADCT)価格
ADCT 株価推移チャート
ADCT 収入
ADC Therapeutics SA
$3.62
1.97%
$0.07
終値： Jan 16, 16:00:00 GMT-5
$3.67
1.38%
$0.04
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$3.55
始値
$3.5
当日レンジ
$3.44 - $3.67
52週レンジ
$1.05 - $4.8
取引高
754.2K
平均取引高
1.1M
1株当たり利益(TTM)
-1.51
配当利回り
--
時価総額
$454.6M
ADCTとは何ですか？
ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. The company is headquartered in Epalinges, Vaud and currently employs 263 full-time employees. The company went IPO on 2020-05-15. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.